Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perillyl alcohol intranasal - NEONC Technologies

Next Previous
Drug Profile

Perillyl alcohol intranasal - NEONC Technologies

Alternative Names: NEO 100; Perillyl-alcohol-intranasal-NEONC-Technologies; POH

Latest Information Update: 04 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NEONC Technologies
  • Developer National Cancer Institute (USA); NEONC Technologies
  • Class Antineoplastics; Monoterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Meningioma
  • Phase I/II Glioma
  • No development reported Glioblastoma
  • Discontinued Cancer

Most Recent Events

  • 28 Sep 2026 NeOnc Technologies plans a Type B meeting with US FDA to discuss registrational pathway of Perillyl alcohol intranasal for Glioma in October
  • 28 Sep 2026 NeOnc Technologies plans a pivotal trial before the end of 2026
  • 24 Sep 2026 NEONC Technologies announces intention to launch Perillyl alcohol intranasal in 2029

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top